The era of "fast fashion" might be over. President Donald Trump's new tariffs on China will make purchases from Shein and Temu more expensive, and that's if the shipments can even get into the U.S. 

Trump's China tariffs include the revocation of a "century-old tax loophole" that had canceled out "tens of billions of dollars in fees on imports," said The Washington Post. That loophole, known as de minimis, skipped import taxes on shipments worth less than $800. 

Most of those imports come from China, home to popular online outlets like Shein and Temu, which are "responsible for an estimated 30% of packages shipped daily" to the U.S., said the Post. Without de minimis, prices on those shipments "could go up an average of 30%."

How will US customers be affected?
American shoppers are worried the new tariffs "will get in the way of their retail therapy," said The Guardian. But a $1 pack of T-shirts from Temu might now become a $2 pack, which is still pretty cheap, and some observers think the changing landscape could even strengthen fast fashion's hold on U.S. consumers. The bigger concern is that "small and medium-sized enterprises won't survive or will face significant challenges," Sheng Lu, a fashion professor at the University of Delaware, said to the Post.

Trump's action is a "big threat to little shipments," said The Wall Street Journal. Ending de minimis will strain the government. Customs and Border Protection will have to spend about $5 per package to treat small shipments "like other imports." That adds up. The new requirements will result in "hundreds of millions of dollars in costs to the government, requiring thousands more customs officers."

What does this mean for American businesses?
The crackdown will hurt Shein and Temu but will "help Amazon," said the Financial Times. The American company has sought to fend off its Chinese competition by creating Amazon Haul, which features products under $20. The end of de minimis is "favorable to Amazon," Andy Wu, an assistant business professor at Harvard University, said to the Times. 

Another American tech giant, Meta, could be hurt. The tariffs could drive Chinese advertisers to "pull back on spending" on Meta's platforms, said Investor's Business Daily. That would be a "negative for ad platforms."

For people struggling to conceive, typical fertility treatment options like in vitro fertilization, or IVF, can be taxing physically, emotionally and financially. However, advances in technology are helping to improve another less painful and costly option for treating infertility, known as in vitro maturation, or IVM.

What's the difference between IVM and IVF?
In vitro maturation could "reduce the cost and time that fertility patients spend at the doctor's office and mitigate the side effects," said The Atlantic. While IVF "relies on hormone injections to ripen a crop of eggs inside the body," IVM involves "collecting immature eggs from the ovaries and maturing them in the lab."

IVM is considerably less invasive and gentler on the patient than IVF. The latter requires women to endure "multiple hormonal injections during the egg retrieval process," said the American Pregnancy Association. Because IVM "matures the eggs after they have been retrieved," hormonal injections are unnecessary. With fewer injections, exams and labs needed and a shorter time for the treatment, the cost of IVM procedures is "expected to be much lower than for IVF."

Who can benefit from IVM?
Egg donors who have undergone multiple retrieval cycles could be good candidates for IVM. It's also a good option for those deemed "hyper-responders," patients whose "ovaries naturally develop more follicles each month, thanks to their young age or conditions such as polycystic ovary syndrome," said The Atlantic. These patients are at the highest risk for dangerous IVF side effects, like ovarian hyperstimulation syndrome, so IVM "could be a safer choice and an effective one."

It could also be helpful to cancer patients, "many of whom don't have time to undergo a lengthy IVF cycle before beginning cancer treatment that threatens their fertility," said The Atlantic. In the fertility industry, said Dina Radenkovic, the CEO of biotech company Gameto, to The Atlantic, there's a "growing recognition that fertility treatments must be not only effective but also more humane."